U.S. markets closed

Nuo Therapeutics, Inc. (AURX)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.64990.0000 (0.00%)
At close: 3:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6499
Open0.7500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.4250 - 0.7500
52 Week Range0.2020 - 1.2200
Volume16,886
Avg. Volume8,831
Market Cap15.417M
Beta (5Y Monthly)4.81
PE Ratio (TTM)N/A
EPS (TTM)-0.0410
Earnings DateAug 17, 2020 - Aug 21, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services
    PR Newswire

    Nuo Therapeutics Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services

    Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4). On April 13, 2021, Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo (available at the URL at the bottom of this release) that Medicare will cover autologous platelet-rich plasma (PRP) for treatment of chronic non-healing diabetic wounds (DFUs) under section 1862(a)(1)(A) of the Social Security Act. This final decision follows the favorable proposed decision memo which was published December 21, 2020 and followed by a thirty-day public comment period. In its final decision memo, CMS concluded that the coverage for DFUs would be for a duration of 20 weeks and limited to devices whose FDA cleared indications include the management of exuding cutaneous wounds such as DFUs. Coverage of autologous PRP beyond 20 weeks for DFUs and for the treatment of all chronic, non-healing wounds will be determined by local Medicare Administrative Contractors (MACs).

  • Nuo Therapeutics Announces Recapitalization and Exchange Agreement that Simplifies Capital Structure
    PR Newswire

    Nuo Therapeutics Announces Recapitalization and Exchange Agreement that Simplifies Capital Structure

    Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the closing of a recapitalization and exchange agreement between the Company, Deerfield Management and affiliates thereof (Deerfield Investors), and senior secured noteholders (Noteholders) whereby the Series A Preferred Stock held by the Deerfield Investors was exchanged for 2,700,000 shares of common stock concurrent with the cancellation and conversion of the senior secured notes into 838,487 shares of common stock and the purchase of 487,500 of shares of common stock for cash by members of the Noteholder group. In addition, Lawrence S. Atinsky, the Deerfield Investors' representative on the Company's board resigned his board position concurrent with the closing of the transaction. The shares of Series A preferred stock were cancelled in full and the Company now has only common stock outstanding and no debt outstanding. The conversion of the approximately $330,000 of senior secured note principal and accrued interest and purchase of shares of common stock were transacted at $0.40 per share. Five-year warrants with a strike price of $0.40 to purchase approximately 3,977,961 shares of common stock were issued in conjunction with the conversion of the senior notes and the purchase of common stock for cash. The original warrants issued in 2019 in conjunction with the issuance of the senior notes were cancelled. Following the closing of the transaction, the Company's total shares of common stock outstanding are approximately 29.2 million shares. Further details are available in a Current Report on 8-K filing made today with the Securities and Exchange Commission.